Since reporting in November that its promising hepatitis C drug ACH-3102 helped clear the virus from 100% of patients in a small clinical trial, shares in Achillion Pharmaceuticals Sovaldi last year revolutionized hepatitis C treatment. Sovaldi cast aside reliance on side-affect-laden peginterferon and cut patient treatment times in half, to 12 weeks, all while delivering functional cure rates of 90% or more.